Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn’s Disease: A Canadian Multi-Centre Observational Cohort Study

BACKGROUND: Ustekinumab (UST), an anti-IL12/23 inhibitor is indicated for moderate-to-severe Crohn’s disease (CD). However, it is unclear if patients treated with UST are at increased risk for postoperative complications. AIM: To evaluate the postoperative safety outcomes in UST-treated CD patients....

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Can Assoc Gastroenterol
Asıl Yazarlar: Shim, Hang Hock, Ma, Christopher, Kotze, Paulo G, Seow, Cynthia H, Al-Farhan, Heba, Al-Darmaki, Ahmed K, Pang, Jack X Q, Fedorak, Richard N, Devlin, Shane M, Dieleman, Levinus A, Kaplan, Gilaad G, Novak, Kerri L, Kroeker, Karen I, Halloran, Brendan P, Panaccione, Remo
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2018
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6507292/
https://ncbi.nlm.nih.gov/pubmed/31294352
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy013
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller